We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
18 result(s) found, displaying 1 to 10
-
Jun-2025Prescription medicine evaluationActive ingredient: burosumab.
-
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CRYSVITA burosumab 10 mg/mL solution for injection in a 5 mL vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CRYSVITA burosumab 30 mg/mL solution for injection in a 5 mL vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CRYSVITA burosumab 20 mg/mL solution for injection in a 5 mL vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for POTELIGEO mogamulizumab 4 mg/mL concentrate for solution for infusion.
-
Australian public assessment report (AusPar)Crysvita (burosumab) for the treatment of X-linked hypophosphataemia (XLH)
-
-
Prescription medicine registrationActive ingredients: burosumab.